Restricted accessBrief reportFirst published online 2019-10
Role of Radiation Therapy in Younger and Older Adults with Primary Mediastinal Large B Cell Lymphoma in Rituximab Era: A U.S. Population-Based Analysis
The role of mediastinal radiotherapy (RT) in primary mediastinal large B cell lymphoma is controversial. We used the Surveillance, Epidemiology and End Results program 18 database to identify the role after rituximab approval. Among 474 patients included, 65.8% were 18–39 years old and 34.2% were 40–59 years old; 45.8% received RT. Univariate analysis showed that disease stage and race could affect survival. After adjusting for stage and race, RT was correlated with prognosis in patients aged 40–59 years (none/unknown vs. RT, hazard ratio = 2.898, p = 0.034). However, in patients aged 18–39 years, this impact was not significant. Omission of RT in selected young patients may be considered.
Get full access to this article
View all access options for this article.
References
1.
StevenHS, EliasC, StefanoAP, et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasm. Blood. 2016; 127(20):2375–90.
2.
Cazals-HatemD, LepageE, BriceP, et al.Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA (Groupe d'Etude des Lymphomes de l'Adulte) study. Am J Surg Pathol. 1996; 20(7):877–88.
3.
AddisBJ, IsaacsonPG. Large cell lymphoma of the mediastinum: a B-cell tumour of probable thymic origin. Histopathology. 1986; 10(4):379–90.
4.
LiuPP, WangKF, XiaY, et al.Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis. Medicine (Baltimore). 2016; 95(27):e4054.
5.
SavageK, Al-RajhiN, VossN, et al.Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol. 2006; 17(1):123–30.
6.
RiegerM, OsterborgA, PettengellR, et al.Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group study. Ann Oncol. 2011; 22(3):664–70.
7.
VassilakopoulosTP, PangalisGA, KatsigiannisA, et al.Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist. 2012; 17(2):239–49.
8.
AvigdorA, SirotkinT, KedmiM, et al.The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol. 2014; 93(8):12.
9.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987–94.
10.
SehnLH, BerryB, ChhanabhaiM, et al.The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5):1857–61.
11.
ZhouZ, SehnLH, RademakerAW, et al.An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014; 123(6):837–42.
12.
LazzarinoM, OrlandiE, PaulliM, et al.Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol. 1997; 15(4):1646–53.
SwerdlowSH, CampoE, HarrisNL (Eds), et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC Press; 2008.
15.
LymanGH, DaleDC, FriedbergJ, et al.Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004; 22(21):4302–11.
16.
ZinzaniPL, MartelliM, MagagnoliM, et al.Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients. Blood. 1999; 94(10):3289–93.
17.
ZinzaniPL, MartelliM, BendandiM, et al.Primary mediastinal large B-cell lymphoma with sclerosis: a clinical study of 89 patients treated with MACOP-B chemotherapy and radiation therapy. Haematologica. 2001; 86(2):187–91.
18.
DunleavyK, PittalugaS, MaedaLS, et al.Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013; 368(15):1408–16.
19.
MartelliM, CerianiL, ZuccaE, et al.[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 Study. J Clin Oncol. 2014; 32(17):1769–75.
20.
CavalliF, CerianiL, ZuccaE. Functional imaging using 18-fluorodeoxyglucose PET in the management of primary mediastinal large B-cell lymphoma: the contributions of the International Extranodal Lymphoma Study Group. Am Soc Clin Oncol Educ Book. 2016; 35:e368–75.
21.
WarrenS, GatesO. Multiple primary malignant tumors: a survey of the literature and a statistical study. Am J Cancer. 1932; 16:1358–414.
22.
MaraldoMV, BrodinNP, AznarMC, et al.Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol. 2013; 24(8):2113–8.
23.
van NimwegenFA, SchaapveldM, CutterDJ, et al.Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma. J Clin Oncol. 2016; 34(3):235–43.
24.
CarverJR, ShapiroCL, NgA, et al.American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol. 2007; 25(25):3991–4008.
